Joint Formulary & PAD

Melatonin - Parkinson's disease

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Modified release tablets
Associated Icons :
BNF SPC
Un
Restrictions / Comments :
Important
Preferred

On specialist recommendation

Melatonin 2mg MR tablets are the recommended preferred 1st line product

Prescribe generically.  Circadin is NON-FORMULARY

 

Status 2

Blue
Formulations :
  • Immediate release tablets
Associated Icons :
BNF SPC
Un
Restrictions / Comments :
Important

If immediate onset of action is required or crushed to aid swallowing

On specialist recommendation

 

 

Status 3

Blue
Formulations :
  • Oral solution
Associated Icons :
BNF SPC
Un
Restrictions / Comments :
Important

Reserved ONLY if feeding tube in situ, or significant swallowing difficulties, and the use of the whole or crushed tablets are unsuitable

On specialist recommendation

 

 

Status 4

Non Formulary
Formulations :
  • Capsules
Associated Icons :
BNF SPC
NFD1
Restrictions / Comments :

Not a cost effective option

PAD Profile

ChemicalSubstance :
Melatonin
Indication :
Parkinson's disease
Group Name :
Keywords :
RBD, rapid eye movement disorder, PD, REM
Brand Names Include :
Important Information :

Rapid eye movement  sleep behaviour disorder. (RBD)

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3
Traffic Light Entries :
4

Other Indications

Below are listed other indications that Melatonin is used to treat.

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed that melatonin may be considered to treat rapid eye movement sleep behaviour disorder (RBD) in people with Parkinson's Disease and sleep disturbance (unlicensed use), on request from a Parkinson's specialist.

In all patients, sleep hygiene and behavioural interventions should be tried prior to considering medication for sleep disorders and should continue to be used alongside melatonin. Sleep | Healthy Surrey

Where treatment is continued beyond 2 years, patient to be advised of limited safety evidence beyond this timeframe and a discussion should be documented in clinical notes.

A BLUE (on specialist recommendation) has been agreed.